Share Share Share

Low-Burden TP53 Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and JAK2 Status

BLOOD

Kubesova, B; Pavlova, S; Malcikova, J; Kabathova, J; Radova, L; Tom, N; Tichy, B; Plevova, K; Kantorova, B; Fiedorova, K; Kissova, J; Gisslinger, B; Gisslinger, H; Mayer, J; Kralovics, R; Pospisilova, S; Doubek, M, 2016: Low-Burden TP53 Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and JAK2 Status. BLOOD 128(22)

Research Groups:

• Genomics Core Facility
• Medical Genomics

CEITEC authors:

• Jitka Malčíková, Ph.D.
• Lenka Radová, Ph.D.
• Boris Tichý, Ph.D.
• Prof. Jiří Mayer
• Prof. Šárka Pospíšilová, Ph.D.
• Prof. Michael Doubek, Ph.D.
• Karla Plevová, Ph.D.
• Šárka Pavlová, Ph.D.